Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 665-671

  Valdezate, Sylvia ^a   Vindel, Ana ^a   Echeita, Aurora ^a   Baquero, Fernando ^a   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GLUTAMINE; ISOLEUCINE; LEUCINE; METHIONINE; NALIDIXIC ACID; NUCLEOTIDE; PHENYLALANINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CYSTIC FIBROSIS; GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

4-QUINOLONES; AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PHENOTYPE; RESERPINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STENOTROPHOMONAS MALTOPHILIA; UNCOUPLING AGENTS;

EID: 0036167743     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.665-671.2002     Document Type: Article

References (42)

1. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia
2. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis
3. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases
4. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit topoisomerase IV
5. Emergence of ofloxacin-resistant Citrobacterfreundii and Pseudomonas maltophilia after ofloxacin therapy
6. Cloning and characterization of a DNA gyrase gyrA gene from Escherichia coli that confers clinical resistance to 4-quinolones
7. Analysis of mutations to gyrA in quinolone-resistant clinical isolates of Enterobacter cloacae
8. Microbiology and clinical aspects of infection associated with Stenotrophomonas maltophilia
9. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity
10. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region
11. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium
12. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolates from humans and animals
13. Novel quinolone resitance mutations of Escherichia coli DNA gyrase A protein: Enzymatic analysis of the mutant proteins
14. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
15. Mutations in gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli
16. Mechanisms of quinolone resistance
17. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: Novel mutations suggest novel drugtarget interactions
18. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during 1997-1998 respiratory season
19. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
20. Quinolone resistant mutants of Escherichia coli DNA topoisomersase IV parC gene
21. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates
22. A genomic approach to the understanding of Xylella fastidiosa pathogenity
23. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro
24. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid
25. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa
26. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction
27. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
28. Activities of newer fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
29. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium
30. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones
31. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains
32. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998
33. Quinolone-resistance mutation in the topoisomerase IV parC gene of Acinetobacter baumannii
34. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii
35. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs
36. DNA topoisomerases
37. Cloning and nucleotide sequence of Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations
38. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
39. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
40. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa
41. Multiple antibiotic resistance in Stenotrophomonas maltophilia: Involvement of a multidrug efflux system